	US 11,859,006 B2
	Method of treating ectopic ossification or diffuse intrinsic pontine glioma in a subject by administering an anti-ALK2 antibody
Takenobu Katagiri, Saitama (JP); Sho Tsukamoto, Saitama (JP); Keigo Kumagai, Saitama (JP); and Shinnosuke Tsuji, Tokyo (JP)
Assigned to Saitama Medical University, Saitama (JP); and Daiichi Sankyo Company, Limited, Tokyo (JP)
Appl. No. 16/977,572
Filed by SAITAMA MEDICAL UNIVERSITY, Saitama (JP); and DAIICHI SANKYO COMPANY, LIMITED, Tokyo (JP)
PCT Filed Mar. 4, 2019, PCT No. PCT/JP2019/008319 § 371(c)(1), (2) Date Sep. 2, 2020, PCT Pub. No. WO2019/172165, PCT Pub. Date Sep. 12, 2019.
Claims priority of application No. 2018-039066 (JP), filed on Mar. 5, 2018.
Prior Publication US 2021/0009709 A1, Jan. 14, 2021
Int. Cl. A61K 39/00 (2006.01); A61K 39/395 (2006.01); C07K 16/28 (2006.01); C12Q 1/6883 (2018.01)

CPC C07K 16/2896 (2013.01) [C12Q 1/6883 (2013.01); A61K 39/3955 (2013.01); A61K 2039/505 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/156 (2013.01)]

19 Claims

1. A method for binding a mutated ALK2 in a subject, comprising:

administering to a subject that has an active mutation in ALK2 an anti-ALK2 antibody or an antigen-binding fragment thereof or a pharmaceutical composition comprising an anti-ALK2 antibody or an antigen-binding fragment thereof;

wherein the active mutation in ALK2 comprises at least one mutation selected from L196P, delP197_F198insL, R202I, R206H, Q207E, R258S, R258G, G325A, G328E, G328R, G328W, G356D, and R375P, relative to SEQ ID NO: 1, but does not have a mutation of an amino acid residue at position 330 of SEQ ID NO: 1,

wherein the subject has ectopic ossification or diffuse intrinsic pontine glioma (DIPG).